Literature summary for 3.4.15.1 extracted from

Wu, C.K.; Luo, J.L.; Tsai, C.T.; Huang, Y.T.; Cheng, C.L.; Lee, J.K.; Lin, L.Y.; Lin, J.W.; Hwang, J.J.; Chiang, F.T.
Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure (2010), Pharmacogenomics J., 10, 46-53.

Search for more literature for 3.4.15.1

Application

Application	Comment	Organism
medicine	evaluation of effects of angiotensin-converting enzyme inhibitors and pharmacogenetic interaction on the survival of the patients with diastolic heart failure, overview	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
additional information	influence of ACE gene insertion/deletion polymorphisms, rs1799752, D-and I-alleles, on ACE inhibitor effects in treatment of heart failure, comparison to effects of polymorphisms of angiotensionogen gene, i.e. T174M, M235T, G6A, A20C, G152A, and G217A, and of the A1166C polymorphisms of the angiotensin II type I receptor, overview. The genetic variants in the renin-angiotensin system genes are associated with long-term mortality and cardiovascular events in the patients with diastolic heart failure, but can be modified by the use of ACE inhibitors	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
additional information	use of ACE inhibitor is associated with a significant decrease in long-term mortality and cardiovascular events in the patients with diastolic heart failure	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
heart	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
ACE	-	Homo sapiens

General Information

General Information	Comment	Organism
malfunction	use of ACE inhibitor is associated with a significant decrease in long-term mortality and cardiovascular events in the patients with diastolic heart failure	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)